•
Dec 31, 2021

Globus Medical Q4 2021 Earnings Report

Globus Medical reported an increase in worldwide net sales and a decrease in GAAP net income for the fourth quarter of 2021.

Key Takeaways

Globus Medical's Q4 2021 results showed a 7.1% increase in worldwide net sales compared to Q4 2020, reaching $250.0 million. GAAP net income decreased by 71.5% to $15.1 million, while non-GAAP diluted EPS was $0.49. The company's Enabling Technology momentum was driven by the clinical superiority of ExcelsiusGPS®, with a record $25 million in revenue.

Worldwide net sales increased by 7.1% to $250.0 million compared to Q4 2020.

GAAP net income for the quarter was $15.1 million.

GAAP diluted EPS was $0.14, and non-GAAP diluted EPS was $0.49.

Non-GAAP adjusted EBITDA was $85.2 million, representing 34.1% of net sales.

Total Revenue
$250M
Previous year: $233M
+7.1%
EPS
$0.49
Previous year: $0.58
-15.5%
Adjusted EBITDA as % of sales
85,179,000%
Previous year: 36.2%
+235301005.0%
Gross Profit
$188M
Previous year: $173M
+9.1%
Cash and Equivalents
$193M
Previous year: $239M
-19.4%
Free Cash Flow
$59.2M
Previous year: $66.1M
-10.5%
Total Assets
$1.96B
Previous year: $1.68B
+16.5%

Globus Medical

Globus Medical

Globus Medical Revenue by Segment

Globus Medical Revenue by Geographic Location

Forward Guidance

The Company announced full year 2022 guidance with expected net sales of $1.025 billion and non-GAAP diluted earnings per share of $2.10.

Positive Outlook

  • Expected net sales of $1.025 billion for full year 2022.
  • Non-GAAP diluted earnings per share of $2.10 for full year 2022.

Revenue & Expenses

Visualization of income flow from segment revenue to net income